{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:12:48Z","timestamp":1781730768140,"version":"3.54.5"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019274","name":"National Institute of Mental Health and Neurosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MH57440"],"award-info":[{"award-number":["MH57440"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.schres.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T23:56:08Z","timestamp":1729468568000},"page":"315-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia"],"prefix":"10.1016","volume":"274","author":[{"given":"Daniela L.","family":"Uliana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.10.003_bb0005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neubiorev.2018.12.003","article-title":"From \u201cbedside\u201d to \u201cbench\u201d and back: a translational approach to studying dopamine dysfunction in schizophrenia","volume":"110","author":"Abi-Dargham","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.schres.2024.10.003_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113155","article-title":"Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - an update of recent progress","volume":"214","author":"Amin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.schres.2024.10.003_bb0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.schres.2024.10.003_bb0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S1092852916000316","article-title":"Psychotic disorders in DSM-5 and ICD-11","volume":"21","author":"Biedermann","year":"2016","journal-title":"CNS Spectr."},{"issue":"56","key":"10.1016\/j.schres.2024.10.003_bb0025","first-page":"62","article-title":"Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs","volume":"17","author":"Blair","year":"1992","journal-title":"Nurse Pract."},{"key":"10.1016\/j.schres.2024.10.003_bb0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/nedt.2006.2.4.531","article-title":"Cognitive deficits and functional outcome in schizophrenia","volume":"2","author":"Bowie","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2024.10.003_bb0035","first-page":"47","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2024.10.003_bb0040","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF02246095","article-title":"Habit-forming actions of nomifensine in nucleus accumbens","volume":"122","author":"Carlezon","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1460-9568.1993.tb00479.x","article-title":"Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo","volume":"5","author":"Chergui","year":"1993","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0050","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.schres.2024.10.003_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2021.697284","article-title":"Striatal control of movement: a role for new neuronal (sub-) populations?","volume":"15","author":"Fieblinger","year":"2021","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110626","article-title":"Biological hypotheses, risk factors, and biomarkers of schizophrenia","volume":"120","author":"Fi\u0161ar","year":"2023","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0065","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1523\/JNEUROSCI.21-13-04915.2001","article-title":"Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons","volume":"21","author":"Floresco","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0070","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nn1103","article-title":"Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission","volume":"6","author":"Floresco","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41386-021-01132-0","article-title":"The role of prefrontal cortex in cognitive control and executive function","volume":"47","author":"Friedman","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2217\/fnl.14.63","article-title":"The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia","volume":"10","author":"Ghoshal","year":"2015","journal-title":"Future Neurol."},{"key":"10.1016\/j.schres.2024.10.003_bb0085","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1017\/S146114571400056X","article-title":"Corresponding decrease in neuronal markers signals progressive parvalbumin neuron loss in MAM schizophrenia model","volume":"17","author":"Gill","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.10.003_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0925-4927(94)90011-6","article-title":"Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia","volume":"55","author":"Goldberg","year":"1994","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2024.10.003_bb0095","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0306-4522(83)90135-5","article-title":"Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization","volume":"10","author":"Grace","year":"1983","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2024.10.003_bb0105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0306-4522(83)90136-7","article-title":"Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--2. Action potential generating mechanisms and morphological correlates","volume":"10","author":"Grace","year":"1983","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2024.10.003_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512374","article-title":"Insights into the mechanism of action of antipsychotic drugs derived from animal models: standard of care versus novel targets","volume":"24","author":"Grace","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.schres.2024.10.003_bb0115","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.10.003_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuroscience.2014.10.008","article-title":"The place of dopamine in the cortico-basal ganglia circuit","volume":"282","author":"Haber","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2024.10.003_bb0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/7854_2010_43","article-title":"Hippocampal pathology in schizophrenia","volume":"4","author":"Heckers","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115214","article-title":"Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation","volume":"406","author":"Horska","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.schres.2024.10.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment: Meta-analysis of imaging studies","volume":"69","author":"Howes","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.brainresrev.2007.05.004","article-title":"Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex","volume":"56","author":"Ikemoto","year":"2007","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.schres.2024.10.003_bb0145","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2013.00086","article-title":"Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of \u201cparadoxical\u201d antidepressant responses in young persons","volume":"4","author":"Karanges","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.schres.2024.10.003_bb0160","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0165","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archgenpsychiatry.2010.10","article-title":"Increased synaptic dopamine function in associative regions of the striatum in schizophrenia","volume":"67","author":"Kegeles","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2024.10.003_bb0180","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0185","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuron.2011.03.025","article-title":"Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli","volume":"70","author":"Lammel","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2024.10.003_bb0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res."},{"issue":"Unit9","key":"10.1016\/j.schres.2024.10.003_bb0195","first-page":"43","article-title":"The MAM rodent model of schizophrenia","volume":"9","author":"Lodge","year":"2013","journal-title":"Curr. Protoc. Neurosci. Chapter"},{"key":"10.1016\/j.schres.2024.10.003_bb0200","doi-asserted-by":"crossref","first-page":"11424","DOI":"10.1523\/JNEUROSCI.2847-07.2007","article-title":"Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia","volume":"27","author":"Lodge","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF03033801","article-title":"Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia","volume":"14","author":"Lodge","year":"2008","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.schres.2024.10.003_bb0210","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbr.2009.01.031","article-title":"Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia","volume":"204","author":"Lodge","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2024.10.003_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107857","article-title":"Sex differences in the long-term effects of past stress on alcohol self-administration, glucocorticoid sensitivity and phosphodiesterase 10A expression","volume":"164","author":"Logrip","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0220","doi-asserted-by":"crossref","DOI":"10.3791\/55718","article-title":"Novel object recognition test for the investigation of learning and memory in mice","author":"Lueptow","year":"2017","journal-title":"JoVE"},{"key":"10.1016\/j.schres.2024.10.003_bb0225","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0230","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuron.2017.02.027","article-title":"Rethinking the pedunculopontine nucleus: from cellular organization to function","volume":"94","author":"Mena-Segovia","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2024.10.003_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.600178","article-title":"PDE10A inhibitors\u2014clinical failure or window into antipsychotic drug action?","volume":"14","author":"Menniti","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0245","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tins.2014.12.005","article-title":"Translating the MAM model of psychosis to humans","volume":"38","author":"Modinos","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0250","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.biopsych.2006.01.003","article-title":"A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia","volume":"60","author":"Moore","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.003_bb0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2024.05.019","article-title":"Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: a randomized proof-of-concept clinical trial","volume":"270","author":"Mukai","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.10.003_bb0260","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1523\/JNEUROSCI.15-05-03622.1995","article-title":"Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input","volume":"15","author":"O\u2019Donnell","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0265","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.psyneuen.2014.05.005","article-title":"Alterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophrenia","volume":"47","author":"Perez","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.schres.2024.10.003_bb0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fnsys.2016.00104","article-title":"Cortico-striatal-thalamic loop circuits of the salience network: a central pathway in psychiatric disease and treatment","volume":"10","author":"Peters","year":"2016","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108040","article-title":"Social dysfunction in the neurodevelopmental model of schizophrenia in male and female rats: behavioural and biochemical studies","volume":"170","author":"Potasiewicz","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0280","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1016\/j.bmcl.2012.07.072","article-title":"Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia","volume":"22","author":"Raheem","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.schres.2024.10.003_bb0285","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0290","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2024.10.003_bb0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2024.10.003_bb0300","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1054-3589(08)60841-8","article-title":"The phasic reward signal of primate dopamine neurons","volume":"42","author":"Schultz","year":"1998","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.schres.2024.10.003_bb0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2024.10.003_bb0310","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1017\/S1355617717001114","article-title":"Evolving notions of schizophrenia as a developmental neurocognitive disorder","volume":"23","author":"Seidman","year":"2017","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.schres.2024.10.003_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/259349","article-title":"Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders","volume":"2012","author":"Shen","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.schres.2024.10.003_bb0320","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","article-title":"A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia","volume":"65","author":"Simpson","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2024.10.003_bb0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.05.009","article-title":"Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia","volume":"163","author":"Sonnenschein","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0335","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/schbul\/sbab047","article-title":"Peripubertal mGluR2\/3 agonist treatment prevents hippocampal dysfunction and dopamine system hyperactivity in adulthood in MAM model of schizophrenia","volume":"47","author":"Sonnenschein","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.10.003_bb0340","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fpsyt.2020.00613","article-title":"Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia","volume":"11","author":"Sonnenschein","year":"2020","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2024.10.003_bb0345","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2024.10.003_bb0350","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neuropharm.2018.11.035","article-title":"Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia","volume":"146","author":"Stark","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.9758\/cpn.2018.16.1.7","article-title":"Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies","volume":"16","author":"Tripathi","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0360","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tins.2012.02.003","article-title":"Are you or aren\u2019t you? Challenges associated with physiologically identifying dopamine neurons","volume":"35","author":"Ungless","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0365","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.10.003_bb0370","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2024.10.003_bb0375","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11682-015-9457-6","article-title":"Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis","volume":"10","author":"Zhang","year":"2016","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.schres.2024.10.003_bb0380","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnmol.2017.00100","article-title":"The phosphodiesterase 10A inhibitor PF-2545920 enhances hippocampal excitability and seizure activity involving the upregulation of GluA1 and NR2A in post-synaptic densities","volume":"10","author":"Zhang","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.schres.2024.10.003_bb0385","series-title":"Dopaminergic System Function and Dysfunction: Experimental Approaches, Neuromethods","first-page":"223","article-title":"The MAM model to study the role of dopamine in schizophrenia","author":"Zhu","year":"2023"},{"key":"10.1016\/j.schres.2024.10.003_bb0390","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1073\/pnas.0813415106","article-title":"Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior","volume":"106","author":"Zweifel","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.schres.2024.10.003_bb0395","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nn.2808","article-title":"Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety","volume":"14","author":"Zweifel","year":"2011","journal-title":"Nat. Neurosci."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642400447X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642400447X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:42:52Z","timestamp":1757349772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099642400447X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":79,"alternative-id":["S092099642400447X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.10.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}